+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Di/tri-peptide transporters as drug delivery targets: regulation of transport under physiological and patho-physiological conditions



Di/tri-peptide transporters as drug delivery targets: regulation of transport under physiological and patho-physiological conditions



Current Drug Targets 4(5): 373-388



Two human di/tri-peptide transporters, hPepT1 and hPepT2 have been identified and functionally characterized. In the small intestine hPepT1 is exclusively expressed, whereas both PepT1 and PepT2 are expressed in the proximal tubule. The transport via di/tri-peptide transporters is proton-dependent, and the transporters thus belong to the Proton-dependent Oligopeptide Transporter (POT)-family. The transporters are not drug targets per se, however due to their uniquely broad substrate specificity; they have proved to be relevant drug targets at the level of drug transport. Drug molecules such as oral active beta-lactam antibiotics, bestatin, prodrugs of aciclovir and ganciclovir have oral bioavailabilities, which largely are a result of their interaction with PepT1. In the last few years an increasing number of studies concerned with regulation of di/tri-peptide transporter capacity have appeared. Studies on receptor-mediated regulation has shown that both PepT1 and PepT2 is down-regulated by long-term exposure to epidermal growth factor (EGF) due to a decreased gene transcription. PepT1-mediated transport is up-regulated by certain substrates and in response to fasting and starvation at the level of increased gene transcription. PepT1-mediated transport is up-regulated by short-term exposure to receptor agonists such as EGF, insulin, leptin, and clonidine, and down-regulated by VIP. Overall, the regulation of di/tri-peptide transport may be contributed to 1) changes in apical proton-motive force 2) recruitment of di/tri-peptide transporters from vesicular storages 3) changes in gene transcription/mRNA stability. The aim of the present review is to discuss physiological, patho-physiological and drug-induced regulation of di/tri-peptide transporter mediated transport.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034722719

Download citation: RISBibTeXText

PMID: 12816347


Related references

Di / tri-Peptide Transporters as Drug Delivery Targets: Regulation of Transport Under Physiological and Patho-physiological Conditions. Current Drug Targets 4(5): 373-388, 2003

(Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Peptide Transporters: Structure, Function, Regulation and Application for Drug Delivery. Current Drug Metabolism 5(1): 85-94, 2004

Mammalian peptide transporters as targets for drug delivery. Trends in Pharmacological Sciences 23(9): 434-440, 2002

Lessons from (patho)physiological tissue stiffness and their implications for drug screening, drug delivery and regenerative medicine. Advanced Drug Delivery Reviews 63(4-5): 269-276, 2011

Poly ribo nucleotide incorporation in human leukocytes under physiological and patho physiological conditions. Verhandlungen der Deutschen Gesellschaft fuer Innere Medizin 79: 363-366, 1973

Regulation of contraction and relaxation by Ca2+ in physiological and patho-physiological situation of myocardium. Journal of Pharmacological Sciences 91(Suppl. I): 26P, 2003

New aspects of nitric oxide regulation under patho-physiological conditions during pregnancy. Nitric Oxide 2(5): 313, 1998

An improved model of circulation with synchronous recording of pressure and flow and of integrated or differentiated values under various physiological and patho physiological conditions. Pfluegers Archiv European Journal Of Physiology-2: 151-152, 1969

Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 38(7-8): 1022-1042, 2008

Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. Journal of Clinical Investigation 101(12): 2761-2767, 1998

Peptide transporters: structure, function, regulation and application for drug delivery. Current Drug Metabolism 5(1): 85-94, 2004

High-affinity sulfate transporters in Arabidopsis: physiological roles and regulation of transport activities. Sulfur transport and assimilation in plants in the Post Genomic Era Papers from the 6th International Workshop on Plant Sulfur Metabolism, Chiba, Japan, 17-21 May, 2005: 37-38, 2005

Investigations of the proteinase inhibitor capacity of human bronchial mucus the content of low molecular inhibitor and alpha 1 anti trypsin under physiological and patho physiological conditions. Pneumonologie 147(1): 13-20, 1972

Physiological transport forces govern drug distribution for stent-based delivery. Circulation 104(5): 600-605, 2001

Effect of some physiological and non-physiological compounds on the phase transition temperature of thermoresponsive polymers intended for oral controlled-drug delivery. International Journal of Pharmaceutics (Kidlington) 222(2): 259-270, 17 July, 2001